Claritas Collaborates with CMAX to Initiate P-I Study of R-107 for Pulmonary Arterial Hypertension
Shots: Amgen entered into an agreement with Abilita Bio for the development of therapies utilizing Abilita’s Enabled Membrane Protein (EMP) technology targeting certain integral membrane proteins The focus of the agreement is to discover and develop candidates targeting complex membrane proteins EMP technology is a drug discovery platform targeting GPCRs, ion channels, and transporters to […]Read More
